ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions
  • 2013 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship
  • ACR Late-Breaking Abstract Oral Session
  • ACR Late-Breaking Abstract Poster Session
  • ACR Plenary Session I: Discovery 2013
  • ACR Plenary Session II: Discovery 2013
  • ACR Plenary Session III: Discovery 2013
  • ACR/ARHP Combined Epidemiology Abstract Session
  • ACR/ARHP Combined Pediatrics Abstract Session
  • ACR/ARHP Combined Rehabilitation Abstract Session
  • ARHP Education/Community Programs
  • ARHP Epidemiology and Public Health
  • ARHP Health Services Research
  • ARHP Imaging of Rheumatic Disease: Research Methodology
  • ARHP Noteworthy Abstracts
  • ARHP Orthopedics, Low Back Pain and Rehabilitation: Rehabilitation Sciences
  • ARHP Osteoarthritis - Clinical Aspects: Psychology/Social Sciences
  • ARHP Pediatrics
  • ARHP Rheumatoid Arthritis - Clinical Aspects: Clinical Practice/Patient Care
  • Antiphospholipid Syndrome
  • Antiphospholipid Syndrome: Clinical Manifestations and New Biomarkers in Antiphospholipid Syndrome
  • B cell Function and Targeting in Systemic Lupus Erythematosus
  • B cells in Human and Animal Arthritis
  • B cells in Systemic Lupus Erythematosus
  • Biology and Pathology of Bone and Joint (Bone and Arthritis)
  • Biology and Pathology of Bone and Joint (Cartilage and Osteoarthritis)
  • Biology and Pathology of Bone and Joint I: Cartilage Biology and Osteoarthritis
  • Biology and Pathology of Bone and Joint II: Osteoclast Biology and Arthritis
  • Clinical Practice/Patient Care
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I: Identifying Novel Factors that Facilitate Neovascularization and Cell Trafficking
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II
  • Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II: Mechanisms that contribute to autoimmune inflammation
  • Education/Community Programs
  • Epidemiology and Health Services I
  • Epidemiology and Health Services II & III
  • Epidemiology and Health Services Research I: Comorbidities in Rheumatic Diseases
  • Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis
  • Epidemiology and Health Services Research III: Healthcare Costs and Mortality in Rheumatic Disease
  • Epidemiology and Health Services Research VI: Risk Factors in Rheumatic Disease Susceptibility
  • Epidemiology and Public Health
  • Fibromyalgia, Soft Tissue Disorders and Pain I
  • Fibromyalgia, Soft Tissue Disorders and Pain II
  • Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and Disease Epidemiology
  • Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and Outcome Assessment
  • Genetics and Genomics of Rheumatic Disease I
  • Genetics and Genomics of Rheumatic Disease II
  • Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery
  • Health Services Research, Quality Measures and Quality of Care - Pediatrics, Immunization and Choosing Wisely
  • Health Services Research, Quality Measures and Quality of Care-Rheumatoid Arthritis
  • Imaging in Pediatric Arthritis, Spondyloarthritis and Osteoarthritis
  • Imaging in Rheumatoid Arthritis
  • Imaging of Rheumatic Diseases I: Imaging in Gout, Pediatric, Soft and Connective Tissue Diseases
  • Imaging of Rheumatic Diseases II: Imaging in Spondyloarthritis and Osteoarthritis
  • Imaging of Rheumatic Diseases: Imaging in Vascular and Extra-articular
  • Infection Related Rheumatic Diseases
  • Innate Immunity and Rheumatic Disease
  • Medical Education
  • Metabolic and Crystal Arthropathies I
  • Metabolic and Crystal Arthropathies II
  • Miscellaneous Rheumatic Diseases
  • Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes
  • Miscellaneous Rheumatic and Inflammatory Diseases II: Autoinflammatory Syndromes
  • Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases
  • Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies
  • Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis
  • Orthopedics, Low Back Pain and Rehabilitation
  • Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis
  • Osteoarthritis - Clinical Aspects I: Risk Factors for and Sequelae of Osteoarthritis.
  • Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis.
  • Osteoarthritis I: Therapeutics in Osteoarthritis
  • Osteoarthritis II: Risk Factors and Natural History of Osteoarthritis
  • Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis
  • Pain - Basic Mechanisms
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Autoinflammatory Disease and Systemic Juvenile Idiopathic Arthritis
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis
  • Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Systemic Lupus Erythematosus and Other Disease Outcomes
  • Pediatric Rheumatology - Pathogenesis and Genetics
  • Pediatric Rheumatology-Clinical and Therapeutic Aspects III: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
  • Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile Idiopathic Arthritis
  • Psychology/Social Sciences/Pediatrics
  • Rehabilitation Sciences
  • Research and Health Services
  • Rheumatoid Arthritis - Animal Models I
  • Rheumatoid Arthritis - Animal Models II
  • Rheumatoid Arthritis - Autoantibodies and Citrullinated Proteins
  • Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations
  • Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches
  • Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects V: Observational Studies in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and Outcome Measures in Rheumatoid Arthritis
  • Rheumatoid Arthritis - Human Etiology and Pathogenesis
  • Rheumatoid Arthritis - Pathogenetic Pathways
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics I
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics II
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Novel Treatment Strategies in Rheumatoid Arthritis
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety Issues
  • Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy of Small Molecule Agents
  • Rheumatoid Arthritis-Clinical Aspects III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis
  • Rheumatoid Arthritis: Human Etiology and Pathogenesis II
  • Sjögren's Syndrome: Basic Science
  • Sjögren's Syndrome: Clinical Advances
  • Sjögren's Syndrome: Clinical Aspects
  • Sjögren's Syndrome: Pathogenesis
  • Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical Features of Spondylarthritis
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Clinical and Imaging Aspects of Axial Spondyloarthritis
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Imaging in Axial Spondylarthropathies: Challenges, Advances
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis
  • Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis
  • Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models I
  • Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models II
  • Systemic Lupus Erythematosus - Animal Models
  • Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease
  • Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biologic Therapy
  • Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics
  • Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus
  • Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Disease-modifying Antirheumatic Drugs
  • Systemic Lupus Erythematosus - Clinical Aspects: Pregnancy
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II
  • Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers
  • Systemic Lupus Erythematosus-Clinical Aspects III: Biomarkers, Quality of Life and Disease Indicators, Late Complications
  • Systemic Lupus Erythematosus-Human Etiology and Pathogenesis: Genetics and Genomics
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud's: Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways Mediating Fibrosis
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Clinical Aspects and Therapeutics III
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis, Animal Models and Genetics I: Therapeutic Interventions in Preclinical Animal Models of Scleroderma
  • Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s-Pathogenesis, Animal Models and Genetics: Pathogenesis of Systemic Sclerosis
  • Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's II
  • Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics I
  • Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics II
  • T-cell Biology and Targets in Autoimmune Disease
  • T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation
  • T-cell Biology in Autoimmune Diseases
  • Vasculitis I
  • Vasculitis II
  • Vasculitis III
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology